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INTRODUCTION 
Non-alcoholic fatty liver disease (NAFLD) is the most com-
mon cause of abnormalities in liver function and imaging de-
tected by ultrasonography.1,2 The prevalence of NAFLD is as-
sumed to be 20–30% in Western countries, and the incidence 
in Asian countries is rapidly increasing in parallel with the 
westernization of lifestyle.3-5 The main concern over NAFLD 
arises from its tight correlation with metabolic disorders such 
as obesity, dyslipidemia, and type 2 diabetes mellitus (T2DM).6-9 
Previous studies have revealed the relationship between 
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NAFLD and insulin resistance and/or T2DM.10,11 In addition, 
several recent studies have shown that NAFLD per se can pre-
dict future development of T2DM.12-14 However, all of these 
studies investigated the presence of NAFLD through ultraso-
nography, a crude method for detecting hepatic steatosis that 
requires more than 30% hepatic lipid for detection and is high-
ly subjective with respect to operator’s skill.15
Controlled attenuation parameter (CAP) is a non-invasive 
diagnostic method that digitizes the amount of hepatic fat, 
based on the properties of ultrasonic attenuation by hepatic fat, 
using the central frequency of the Fibroscan® M probe.16 In sev-
eral previous studies on various chronic liver diseases, CAP 
showed significant correlation with hepatic steatosis and con-
siderable diagnostic performance for grading the degree of 
steatosis.17-20 Therefore, this novel parameter enabled research-
ers to investigate the prevalence and severity of NAFLD through 
quantitative measurement of hepatic steatosis with high sen-
sitivity.
In the present study, we investigated the following by using 
CAP 1) the prevalence and the severity of NAFLD according to 
the glucose tolerance status, and 2) factors involved in the as-
sociation between NAFLD and T2DM.
MATERIALS AND METHODS 
Patients
We examined the data of 372 subjects who underwent a health 
check-up from November 2011 to February 2013 at Severance 
Hospital, Yonsei University College of Medicine, Seoul, Korea. 
Subjects who underwent both laboratory testing of biomark-
ers for T2DM and CAP were included. The following exclusion 
criteria were applied.
1) Subjects with chronic liver disease of any etiology other 
than NAFLD [positivity for hepatitis B surface antigen (HBsAg; 
n=4) or hepatitis C antibody (anti-HCV; n=2)]
2) Subjects with potential risk for developing secondary he-
patic steatosis [excessive (>20 g/day) alcohol consumption (n= 
20), medications (n=4; steroid, n=3; tamoxifen, n=1)]
3) Unreliable liver stiffness value (LSV) or LSV measurement 
failure (n=2)
After excluding 32 of 372 participants, a total of 340 subjects 
were included in the final analysis. This study was approved by 
the independent Institutional Review Board of Severance Hos-
pital of Yonsei University College of Medicine and conformed 
to the ethical guidelines of the 1975 Helsinki declaration. All 
patients signed a written informed consent.
Medical examinations and laboratory tests 
Anthropometric data, such as body mass index (BMI) and sys-
tolic and diastolic blood pressure, were measured. A question-
naire was given to all participants to investigate family history 
of diabetes mellitus, frequency and amount of alcohol consump-
tion, and smoking status (never, past, current). T2DM was de-
fined as fasting glucose ≥126 mg/dL, and/or 2-hour post-load-
ing glucose ≥200 mg/dL, and/or hemoglobin A1c (HbA1c) 
≥6.5%, or history of glucose-lowering medications. The pre-
diabetes group included subjects with impaired fasting glyce-
mia (fasting glucose 100 to 125 mg/dL) and/or impaired glu-
cose tolerance [75 g oral glucose tolerance test (OGTT), 140 to 199 
mg/dL], and/or HbA1c 5.7 to 6.4%.21 Hypertension was defined 
as taking anti-hypertensive medication or blood pressure higher 
than 140/90 mm Hg at initial examination. Metabolic syndrome 
was defined according to the criteria established by the Na-
tional Cholesterol Education Program Adult Treatment Panel 
III, except for the determination of abdominal obesity by waist 
circumference. We used a waist circumference cutoff level 
based on the report by the International Diabetes Institute/West-
ern Pacific World Health Organization/International Obesity 
Task Force. Metabolic syndrome was diagnosed if three of the 
five following features were satisfied: 1) waist circumference 
>90 cm in men and >80 cm in women; 2) triglycerides ≥150 
mg/dL (1.7 mmol/L); 3) high-density lipoprotein (HDL) cho-
lesterol <40 mg/dL (1.03 mmol/L) in men and <50 mg/dL (1.29 
mmol/L) in women; 4) blood pressure ≥130/85 mm Hg; and 5) 
fasting plasma glucose ≥100 mg/dL (5.6 mmol/L).
The laboratory tests included serological tests for HBsAg, 
anti-HCV, aspartate aminotransferase, alanine aminotrans-
ferase (ALT), total bilirubin, gamma glutamyltranspeptidase 
(GGT), and lipid profiles (triglycerides and total HDL, and low-
density lipoprotein cholesterol). Biomarkers related to T2DM 
included fasting glucose, fasting insulin, fasting C-peptide, 
HbA1c, glycoalbumin, homeostasis model assessment of in-
sulin resistance of insulin resistance (HOMA-IR), homeostasis 
model assessment of beta cell function (HOMA-β), and high 
sensitive C-reactive protein (hs-CRP). HOMA-IR was calculat-
ed as fasting serum insulin (IU/dL)×fasting serum glucose (mg/
dL)/22.5, and HOMA-β as [20×fasting serum insulin (IU/dL)]/
[fasting serum glucose (mg/dL)-3.5].
Imaging tests
All subjects underwent abdominal ultrasonography and tran-
sient elastography (FibroScan®, EchoSens, Paris, France). Ab-
dominal ultrasonography was performed by two experienced 
hepatologists. Liver steatosis by ultrasonography was assessed 
as absent, mild, moderate, or severe on the basis of the liver-kid-
ney difference in echo amplitude caused by abnormally in-
tense echoes arising from the hepatic parenchyma due to liver 
fat, echo attenuation by fat into the deep portion of liver, and 
blurring of the blood vessel structures in the liver.22 Two hepa-
tologists who performed ultrasonography independently re-
viewed all ultrasonographic findings. In cases of discrepancy, 
a final consensus opinion was adopted.
CAP and liver stiffness measurement were performed on 
the right lobe of the liver through the intercostal spaces with sub-
jects lying in the dorsal decubitus position with the right arm in 
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maximal abduction by one experienced technician who was 
blind to the subjects’ clinical data. The principle of CAP calcu-
lation has been described previously.23 Briefly, CAP measures 
ultrasonic attenuations by the liver fat at 3.5 MHz using signals 
acquired by the FibroScan®, and is simultaneously calculated 
with LSV using the same signals. CAP value and LSV are ex-
pressed as dB/m and kPa, respectively. The median values of 
successful measurements were selected as the representative 
CAP values and LSV. The interquartile range (IQR) was defined 
as the interval containing 50% of valid measurements between 
the 25th and 75th percentiles. As an indicator of variability, 
the ratio of the IQR of CAP values and LSV to the median (IQR/
Table 1. Baseline Characteristics 
Variables
All subjects
(n=340)
Subjects with NGT 
(n=72, 21.2%)
Subjects with pre-diabetes 
(n=202, 59.4%)
Subjects with T2DM  
(n=66, 19.4%)
p value
Demographic variables
Age (yrs) 56±11 48±12 58±9 62±11 <0.001
Male gender 191 (56.2) 36 (50.0) 10.9 (54.0) 46 (69.7) 0.004 
Hypertension 66 (19.4) 15 (20.8) 36 (17.8) 15 (22.7) NS
Metabolic syndrome 85 (25.0) 20 (27.8) 43 (21.3) 22 (33.3) NS
Family Hx of diabetes mellitus 61 (17.9) 11 (15.3) 35 (17.3) 15 (22.7) NS
Alcohol (g/day) 5.2±6.4 5.4±6.0 5.9±6.4 4.2±6.4 NS
Current smoker 72 (21.2) 22 (30.6) 38 (18.9) 12 (18.2) NS
Anthropometric index
Systolic blood pressure (mm Hg) 128±10 115±10 131±10 133±9 NS
Diastolic blood pressure (mm Hg) 79±9 80±8 77±11 83±6 NS
Body mass index (kg/m2) 24.1±3.1 23.0±2.9 24.1±2.9 25.4±3.2 <0.001
Waist circumferences (cm) 83.4±9.2 81.2±9.2 85.1±8.9 87.7±7.5 <0.001
Laboratory variables
Total cholesterol (mg/dL) 168.9±41.2 169.0±48.0 162.2±40.3 188.9±36.4 NS
Triglycerides (mg/dL) 114.3±63.3 98.2±64.1 112.9±58.1 135.9±72.1 <0.001
HDL-cholesterol (mg/dL) 48.9±13.9 48.0±10.3 50.1±14.9 45.0±13.7 NS
LDL-cholesterol (mg/dL) 100.0±29.3 98±24.3 96.1±30.1 114.1±32.3 NS
Aspartate aminotransferase (IU/L) 23.0±8.6 21.7±9.2 23.1±8.1 24.2±9.4 NS
Alanine aminotransferase (IU/L) 23.2±13.3 20.7±13.1 23.1±12.6 26.2±15.1 0.019 
Total bilirubin (mg/dL) 1.1±4.6 1.0±2.2 0.8±0.3 1.9±1.0 NS
Gamma glutamyltransterase (IU/L) 38.3±73.5 35.8±67.3 38.1±83.6 41.4±39.4 NS
Biomarkers related to insulin resistance
Fasting glucose (mg/dL) 101.1±55.0 87.2±12.3 95.4±8.7 137.2±95.0 <0.001
Fasting insulin (µU/mL) 7.1±4.6 5.6±3.3 7.0±4.1 8.6±6.4 <0.001
Fasting C-peptide (ng/mL) 2.2±1.2 1.9±1.1 2.2±1.1 2.5±1.3 0.005 
HbA1c (%) 6.0±0.8 5.5±0.2 5.9±0.2 7.0±1.3 <0.001
Glycoalbumin (%) 12.4±3.6 10.9±1.2 11.6±1.7 16.3±5.9 <0.001
HOMA-IR 1.89±2.20 1.22±0.69 1.69±1.06 3.11±4.28 <0.001
HOMA-β 77.17±54.60 80.50±59.38 79.47±43.92 67.11±75.22 NS
High sensitive C-reactive protein (mg/L) 1.8±3.1 1.6±3.9 1.7±2.8 2.0±2.8 NS
Liver stiffness measurement
Liver stiffness value (kPa) 4.7±2.1 4.4±1.7 4.6±1.6 5.5±3.5 0.003 
Interquartile range (kPa) 0.7±0.4 0.5±1.7 0.7±0.4 0.4±0.1 NS
Interquartile range/median (%) 14.9±9.5 14.8±9.8 17.6±9.7 7.5±2.1 NS
Controlled attenuation parameter
CAP value (dB/m) 246.2±50.4 227.3±47.5 246.9±47.4 264.5±56.1 <0.001
Interquartile range (dB/m) 28.4±16.3 22.5±15.6 31.9±18.0 24.0±13.5 NS
Interquartile range/median (%) 14.0±8.4 12.8±6.4 15.5±10.0 11.8±6.4 NS
NS, not significant (p-value>0.05); NGT, normal glucose tolerance; T2DM, type 2 diabetes mellitus; HDL, high-density lipoprotein; LDL, low-density lipoprotein; 
HbA1c, hemoglobin A1c; HOMA-IR, homeostasis model assessment of insulin resistance; HOMA-β, homeostasis model assessment of beta cell function; CAP, 
controlled attenuation parameter.
Variables are expressed as mean±SD (range) or n (%). 
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Mcap and IQR/M, respectively) was calculated. In this study, 
only measurements with at least 10 valid shots and a success 
rate of at least 60% were considered reliable and were used for 
statistical analysis.24 A CAP value of 250 dB/m was selected as 
the cutoff for presence of steatosis and a CAP value of 300 dB/m 
was the cutoff for moderate to severe steatosis.20
Statistical analysis
Data are expressed as means±standard deviation, median (range), 
or n (%), as appropriate. Categorical data were compared using 
chi-square test and continuous data were compared with in-
dependent t-test. Differences of median CAP values according 
to diabetic group were analyzed with the Kruskal-Wallis test. 
Binary logistic regression analysis was used to identify the fac-
tors associated with T2DM. Correlations between CAP value 
and biomarkers related to T2DM were evaluated by Spearman 
correlation coefficients. A one-way analysis of variance was 
performed to compare HOMA-IR and fasting C-peptide ac-
cording to CAP groups (CAP value <250 vs. CAP value 250–300 
vs. CAP value ≥300). All statistical analyses were performed 
using SPSS 19.0 (SPSS Inc., Chicago, IL, USA) and two-sided p-
values <0.05 were considered significant.
RESULTS
Baseline characteristics
Among the 340 participants (191 men and 139 women), 66 
(19.4%) subjects had T2DM. Among 274 (80.6%) subjects with-
out T2DM, 202 (59.4%) had pre-diabetes and 72 (21.2%) showed 
normal glucose tolerance (NGT). The baseline characteristics 
of study subjects according to patients with and without T2DM 
are shown in Table 1. According to the glucose tolerance status, 
patients with T2DM rather than patients with pre-diabetes or 
NGT were more likely to be older and male (both p<0.05). These 
subjects also had higher BMI, waist circumference, and triglyc-
eride level, as well as elevated biomarkers related to T2DM 
(fasting glucose, fasting insulin, fasting C-peptide, HbA1c, gly-
coalbumin, and HOMA-IR) (all p<0.05). CAP values and LSV 
were also significantly higher in patients with T2DM than those 
with pre-diabetes or NGT (CAP values, 264.5±56.1 dB/m vs. 
246.9±47.4 dB/m vs. 227.3±47.5 dB/m, p<0.001; LSV, 5.5±3.5 
kPa vs. 4.6±1.6 kPa vs. 4.4±1.7 kPa, p=0.003).
Prevalence of NAFLD according to the glucose 
tolerance status
The proportion of subjects with presence of NAFLD (CAP value 
≥250 dB/m) increased according to the glucose tolerance sta-
tus [31.9% (n=23) in NGT; 47.0% (n=95) in pre-diabetes, 57.6% 
(n=38) in T2DM; NGT vs. pre-diabetes, p=0.027; NGT vs. 
T2DM, p=0.003; pre-diabetes vs. T2DM, p=0.157]. The propor-
tion of subjects with moderate to severe NAFLD (CAP value 
≥300 dB/m) also increased according to the glucose tolerance 
status (9.7% in NGT, 15.3% in pre-diabetes, 33.3% in T2DM; 
NGT vs. pre-diabetes, p=0.321; NGT vs. T2DM, p=0.001; pre-
diabetes vs. T2DM, p=0.02) (Fig. 1A). In addition, the proportion 
of subjects with NAFLD diagnosed by ultrasonography dif-
fered according to the glucose tolerance status (27.8% in NGT, 
35.6% in pre-diabetes, 54.5% in T2DM; NGT vs. pre-diabetes, 
p=0.425; NGT vs. T2DM, p=0.024; pre-diabetes vs. T2DM, p= 
0.057). The proportion of subjects with moderate to severe 
NAFLD diagnosed by ultrasonography also increased accord-
Fig. 1. Prevalence of NAFLD according to the glucose tolerance status. (A) Subjects with NAFLD (CAP value ≥250 dB/m) increased according to the glu-
cose tolerance status (31.9% in NGT; 47.0% in pre-diabetes; 57.6% in T2DM) (black bar). Subjects with moderate to severe NAFLD (CAP value ≥300 dB/m) 
increased according to the glucose tolerance status (9.7% in NGT; 15.3% in pre-diabetes; 33.3% in T2DM) (white bar). (B) Subjects with presence of 
NAFLD (diagnosed by ultrasonography) increased according to the glucose tolerance status (27.8% in NGT; 35.6% in pre-diabetes; 54.5% in T2DM) (black 
bar). Subjects with moderate to severe NAFLD (diagnosed by ultrasonography) increased according to the glucose tolerance status (6.9% in NGT; 8.4% in 
pre-diabetes; 22.7% in T2DM) (white bar). NAFLD, non-alcoholic fatty liver disease; CAP, controlled attenuation parameter; NGT, normal glucose toler-
ance; T2DM, type 2 diabetes mellitus.
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ing to the glucose tolerance status (6.9% in NGT, 8.4% in pre-
diabetes, 22.7% in T2DM; NGT vs. pre-diabetes, p=0.406; NGT 
vs. T2DM, p=0.031; pre-diabetes vs. T2DM, p=0.044) (Fig. 1B).
Severity of NAFLD according to the glucose tolerance 
status
Subjects with T2DM had significantly higher median CAP val-
ues than those with NGT (265 dB/m vs. 231 dB/m, p<0.001) or 
pre-diabetes (265 dB/m vs. 245 dB/m, p=0.003). The median 
CAP value was significantly higher in the pre-diabetes group 
than in the NGT group (245 dB/m vs. 231 dB/m, p=0.001) (Fig. 
2A). In subjects with NAFLD (CAP value ≥250 dB/m), the me-
dian CAP values increased according to the glucose tolerance 
status: 259 dB/m in NGT, 278 dB/m in pre-diabetes, and 304 
dB/m in the T2DM group (comparison between groups; 
T2DM vs. NGT, p=0.006; T2DM vs. pre-diabetes, p=0.026; pre-
diabetes vs. NGT, p=0.077) (Fig. 2B). In subjects with NAFLD 
(diagnosed by ultrasonography), the median CAP values also 
increased according to the glucose tolerance status: 265 dB/m 
in NGT, 278 dB/m in pre-diabetes, and 302 dB/m in the T2DM 
group (comparison between groups; T2DM vs. NGT, p=0.042; 
T2DM vs. pre-diabetes, p=0.047; pre-diabetes vs. NGT, p= 
0.484) (Fig. 2C).
Factors associated with T2DM 
In univariate binary logistic regression analyses, T2DM was sig-
nificantly associated with fasting glucose, fasting insulin, fast-
ing C-peptide, HbA1c, glycoalbumin, and HOMA-IR (all p< 
0.05). In addition, among all variables described in Table 1, 
T2DM was associated with age, male gender, BMI, waist circum-
ference, triglyceride, HDL-cholesterol, LSV, and CAP value (all 
p<0.05).
Multivariable logistic regression analysis was performed to 
control for other established risk factors for T2DM and to de-
termine whether CAP value was independently associated with 
T2DM (Table 2). After adjusting for age, gender, BMI, waist 
circumference, triglyceride, HDL-cholesterol, and LSV, sub-
jects with CAP value ≥300 dB/m were found to have a 2.8-fold 
higher risk of having T2DM than those with CAP value <250 
dB/m [p=0.017; odds ratio (OR)=2.83; 95% confidence interval 
(CI), 1.21–6.64]. Subjects with a CAP value of 250–300 dB/m 
had a very similar risk of developing T2DM as those with CAP 
value <250 dB/m (p=0.374; OR=1.10; 95% CI, 0.59–2.16). As ex-
pected, age was also closely related to the risk of T2DM (p<0.001; 
OR=1.07; 95% CI, 1.04–1.11). However, gender, BMI, waist cir-
cumference, triglycerides, HDL-cholesterol, and LSV showed 
no significant associations with T2DM.
Correlation between CAP value and baseline factors 
Biomarkers related to T2DM and other factors were measured 
in all subjects (n=340) to investigate their correlation with CAP 
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Fig. 2. Severity of NAFLD according to the glucose tolerance status. (A) Subjects with T2DM had significantly higher median CAP values than those with 
NGT (265 dB/m vs. 231 dB/m, p<0.001) or pre-diabetes (265 dB/m vs. 245 dB/m, p=0.003). (B) In subjects with NAFLD (CAP value ≥250 dB/m), the median 
CAP value increased according to the glucose tolerance status: 259 dB/m, 278 dB/m, and 304 dB/m in NGT, pre-diabetes, and T2DM groups, respectively 
(comparison between groups: T2DM vs. NGT, p=0.006; T2DM vs. pre-diabetes, p=0.026; pre-diabetes vs. NGT, p=0.077). (C) In subjects with NAFLD (diag-
nosed by ultrasonography), the median CAP values increased according to the glucose tolerance status: 265 dB/m in NGT, 278 dB/m in pre-diabetes, and 
302 dB/m in T2DM group (comparison between groups; T2DM vs. NGT, p=0.042; T2DM vs. pre-diabetes, p=0.047; pre-diabetes vs. NGT, p=0.484). NAFLD, 
non-alcoholic fatty liver disease; CAP, controlled attenuation parameter; T2DM, type 2 diabetes mellitus; NGT, normal glucose tolerance.
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Table 2. Multiple Logistic Regression Analyses of Factors Associated 
with T2DM
Odd ratio (95% CI) p value
Age (yrs) 1.07 (1.04–1.11) <0.001
CAP value (group 0 vs. 1) 1.10 (0.59–2.16) 0.374
CAP value (group 0 vs. 2) 2.83 (1.21–6.64) 0.017
Models controlled for age, gender, BMI, waist circumference, triglycer-
ide, HDL-cholesterol, and LSV.
T2DM, type 2 diabetes mellitus; BMI, body mass index; HDL, high-density lipo-
protein; LSV, liver stiffness value; CI, confidence interval; CAP, controlled at-
tenuation parameter.
Group 0, CAP value <250 dB/m; Group 1, 250 dB/m ≤CAP value <300 dB/m; 
Group 2, CAP value ≥300 dB/m.
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value (Table 3). Among biomarkers related to T2DM, CAP val-
ue showed significant correlation; HOMA-IR (ρ=0.407, p<0.001) 
and fasting C-peptide (ρ=0.402, p<0.001). In addition, CAP val-
ue showed a correlation with fasting insulin (ρ=0.395, p<0.001), 
fasting glucose (ρ=0.379, p<0.001), HbA1c (ρ=0.345, p<0.001), 
hs-CRP (ρ=0.277, p=0.001), and HOMA-β (ρ=0.132, p<0.001). 
Among other factors, CAP value showed significant correla-
tion with BMI (ρ=0.491, p<0.001), triglycerides (ρ=0.458, p< 
0.001), and waist circumference (ρ=0.403, p<0.001). Moreover, 
CAP showed a correlation with ALT (ρ=0.291, p<0.001), GGT 
(ρ=0.268, p<0.001), HDL-cholesterol (ρ=-0.218, p<0.001), and 
total bilirubin (ρ=-0.109, p=0.046). HOMA-IR was significantly 
higher in the group with CAP value ≥300 dB/m than in the 
groups with CAP value between 250–300 or CAP value <250 
dB/m (HOMA-IR, 3.00±1.99 vs. 1.64±1.04 vs. 1.63±2.59, respec-
tively; p<0.001) (Fig. 3A). Subjects with a CAP value >300 dB/
m showed significantly higher fasting C-peptide than those 
with CAP value between 250–300 dB/m or <250 dB/m (fasting 
C-peptide; 2.71±0.95 ng/mL vs. 2.29±1.62 ng/mL vs. 1.97±0.88 
ng/mL, respectively; p<0.001) (Fig. 3B).
DISCUSSION
The important findings of the present study are 1) subjects with 
T2DM had a more severe degree of NAFLD, as represented by 
CAP value, than those with NGT; 2) hepatic fat was a signifi-
cant risk factor for T2DM; and 3) a clear association between 
hepatic fat and insulin resistance was demonstrated.
 In our study, subjects with T2DM had higher BMI, higher tri-
glycerides, and lower HDL cholesterol level than those with-
out T2DM, thus presenting a higher metabolic risk in general. 
The higher mean CAP value in subjects with T2DM in our study 
can be explained in the same context and the metabolic signif-
icance of the CAP value was also demonstrated by its signifi-
cant correlation with BMI (ρ=0.491, p<0.001), triglycerides (ρ= 
0.458, p<0.001), and waist circumference (ρ=0.403, p<0.001). 
Therefore, CAP value may be an additional parameter that can 
supplement the traditional variables representing metabolic 
risk. In addition, considering the fact that NAFLD is now ac-
Table 3. Correlations between CAP Values and Baseline Factors (n=340)
Variable
Correlation
ρ p value 
Biomarkers related T2DM
Fasting glucose (mg/dL) 0.379 <0.001
Fasting insulin (µU/mL) 0.395 <0.001
Fasting C-peptide (ng/mL) 0.402 <0.001
HbA1c (%) 0.345 <0.001
Glycoalbumin (%) 0.097 0.079 
HOMA-IR 0.407 <0.001
HOMA-β 0.132 <0.001
High sensitive C-reactive protein (mg/L) 0.277 0.001 
Other factors 
Body mass index (kg/m2) 0.491 <0.001
Waist circumference (cm) 0.403 <0.001
Total cholesterol (mg/dL) 0.019 0.734 
Triglycerides (mg/dL) 0.458 <0.001
HDL-cholesterol (mg/dL) -0.218 <0.001
LDL-cholesterol (mg/dL) 0.012 0.830 
Aspartate aminotransferase (IU/L) 0.128 0.200 
Alanine aminotransferase (IU/L) 0.291 <0.001
Total bilirubin (mg/dL) -0.109 0.046 
Gamma glutamyltransterase (IU/L) 0.268 <0.001
CAP, controlled attenuation parameter; T2DM, type 2 diabetes mellitus; HbA1c, 
hemoglobin A1c; HOMA-IR, homeostasis model assessment of insulin resis-
tance; HOMA-β, homeostasis model assessment of beta cell function; HDL, 
high-density lipoprotein; LDL, low-density lipoprotein.
Fig. 3. HOMA-IR and fasting C-peptide level according to CAP values. (A) HOMA-IR was significantly higher in the group with CAP value ≥300 dB/m com-
pared with the groups with CAP value of 250–300 or <250 dB/m (HOMA-IR, 3.00±1.99 vs. 1.64±1.04 vs. 1.63±2.59, respectively; p<0.001). (B) Subjects with 
CAP value >300 dB/m showed significantly higher fasting C-peptide than those with CAP value of 250–300 dB/m or <250 dB/m (fasting C-peptide, 
2.71±0.95 ng/mL vs. 2.29±1.62 ng/mL vs. 1.97±0.88 ng/mL, respectively; p<0.001). HOMA-IR, homeostasis model assessment of insulin resistance; CAP, 
controlled attenuation parameter.
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cepted as a hepatic manifestation of metabolic syndrome, the 
CAP value would likely be used as a unique metabolic parame-
ter that specifically targets the liver.
Subjects with T2DM had a high prevalence of NAFLD, ap-
proximately 60%.24,25 Using CAP as a tool, the present study 
confirmed that the prevalence of NAFLD increases according 
to the glucose tolerance status (31.9% in NGT, 47.0% in pre-di-
abetes, and 57.6% in T2DM), which was compatible with the 
previous study.26 Specifically, the prevalence of NAFLD was 
higher when it was diagnosed by CAP than ultrasonography, 
because CAP is a sensitive method for detecting small amount 
(less than 20%) of hepatic fat. In addition, we found that the se-
verity of NAFLD represented by CAP value increased in sub-
jects with T2DM. As far as we are aware of, this is the only study 
to demonstrate quantitative differences in the accumulation 
of hepatic fat according to glucose tolerance status.
In the present study, we investigated the correlation between 
CAP and T2DM-related biomarkers to explain the association 
between the incidence of T2DM and prevalence of NAFLD, as 
well as the differences in hepatic fat accumulation according 
to glucose tolerance status. Among all T2DM-related biomark-
ers, the association between CAP value and HOMA-IR was the 
strongest. Therefore, HOMA-IR may play a key role in linking 
hepatic fat to the incidence of T2DM. Previous studies have 
reported that hepatic fat plays a key role in the impairment of 
insulin-mediated inhibition of hepatic glucose production 
that leads to insulin resistance.27 The mechanism of this NAFLD-
associated hepatic insulin resistance was investigated by mea-
suring hepatic glucose and insulin using a low-dose hyperin-
sulinemic-euglycemic clamp combined with a glucose tra-
cer.28-30 In patients with NAFLD, endogenous glucose produc-
tion was normal but peripheral glucose disposal was markedly 
decreased due to impaired glucose oxidation and glycogen syn-
thesis.
Transient elastography, which was used to measure CAP in 
this study, is a simple, reproducible, non-invasive tool16,20 that 
demonstrated a very strong relationship with insulin resistance, 
a main causative factor of T2DM, and a factor associated with 
obesity. Therefore, it has substantial clinical implications as a 
monitoring tool for NAFLD, and the change in the amount of 
hepatic steatosis in association with an improvement or deteri-
oration in insulin resistance can be dynamically monitored us-
ing the CAP value during follow up. 
There are several limitations in this study that should be ac-
knowledged. The inclusion of participants who are able to af-
ford a health check-up in a tertiary hospital may imply selection 
bias toward older age and high economic status. For this rea-
son, our participants tended to show a higher prevalence of T2DM 
compared with the general population.31 Second, the cross-sec-
tional approach of the present study precludes solid conclu-
sions on the relationship between CAP value and biomarkers 
related to T2DM and on prediction of the prognosis of subjects 
with T2DM according to the degree of hepatic steatosis. There-
fore, there is a need for further study that validates our data us-
ing a large sample cohort with a well-balanced spectrum of age 
and economic status and is designed in a longitudinal manner.
In conclusion, this study proved that subjects with T2DM 
had a higher prevalence of severe NAFLD than those with NGT. 
Moreover, increased hepatic steatosis was significantly associ-
ated with the presence of T2DM, and insulin resistance induced 
by hepatic fat may be an important mechanistic connection. 
Longitudinal prospective studies are necessary to investigate 
the clinical implication of the relationship between CAP value 
and T2DM-related biomarkers and their association with the 
prognosis of T2DM.
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